Every 8-K that Petvivo Holdings (PETVW) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PETVW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PETVW filings page.
PetVivo Holdings, Inc. reported a change in its independent auditors. Stephano Slack LLC resigned as the company’s independent registered public accounting firm, effective July 2, 2026, after auditing the fiscal years ended March 31, 2026 and March 31, 2025. Those audit reports contained no adverse or disclaimed opinions and were not qualified, but the 2026 report included an explanatory paragraph expressing substantial doubt about the company’s ability to continue as a going concern, which is treated as a reportable event. The company states there were no disagreements with Stephano Slack on accounting or auditing matters.
On July 23, 2026, with Audit Committee approval, PetVivo engaged GuzmanGray, A Professional Accountancy Corporation, as its new independent registered public accounting firm for the fiscal year ending March 31, 2027, including interim review periods ending June 30, September 30, and December 31, 2026. PetVivo reports it had not previously consulted GuzmanGray on accounting, auditing, or financial reporting issues.
PetVivo Holdings has signed an Agreement and Plan of Merger to acquire PiezoBioMembrane, Inc. (PBM) in an all‑stock transaction. PBM will merge into a PetVivo subsidiary and, after closing, operate as a wholly owned subsidiary of Cosmeta Corp., PetVivo’s biomaterials-focused operating arm.
PBM shareholders are slated to receive an aggregate of 3,000,000 shares of PetVivo restricted common stock. A first block of up to 1,500,000 shares will be fully vested at closing, while the remaining “Milestone Shares” will be issued but subject to forfeiture unless specified development and regulatory milestones are achieved.
Before closing, PBM must clear defined liabilities and convert or settle all preferred stock, SAFEs, options, warrants and other securities. Closing also depends on PetVivo completing an equity financing with at least $5.0 million in gross proceeds. PBM’s extensive intellectual property portfolio will remain in PBM, and key PBM personnel are expected to stay involved through consulting and service arrangements.
PetVivo Holdings, Inc. entered into a Subscription Agreement to receive $1,000,000 of equity financing in exchange for 1,250,000 shares of restricted common stock. The company received an initial $400,000 on March 13, 2026 and expects the remaining $600,000 on or before April 15, 2026.
The investor also received a purchase option to invest an additional $1,500,000 for 1,875,000 restricted shares, anticipated on or before June 30, 2026, on the same terms. The transaction is a private offering to an accredited investor under Section 4(a)(2) and Regulation D, and the shares are restricted securities subject to Rule 144.
PetVivo Holdings, Inc. reported a change in its Board of Directors. On January 26, 2026, director Spencer Breithaupt resigned from the Board, effective that day. The company states his resignation was not due to any disagreement over operations, policies, or practices.
Following his departure, the Board reduced its size from seven to six directors and does not plan to immediately fill the vacancy, though it may add a seventh director in the future at its discretion. The Board expressed appreciation for Mr. Breithaupt’s leadership, guidance, and contributions during his service.
PetVivo Holdings, Inc. furnished a new investor presentation as part of a current report. Representatives plan to use this January 2026 presentation at investor conferences, in other forums, and on the company’s website.
The presentation is included as Exhibit 99.1 and is furnished under Regulation FD and Item 7.01, meaning it is not deemed filed for liability purposes under the Exchange Act and is not automatically incorporated into other securities filings unless specifically referenced. Management notes that the information is summary in nature and may be updated over time through future SEC reports, press releases, or other public disclosures.
PetVivo Holdings, Inc. reported that its Board of Directors recognized the resignation of director Michael Eldred, effective January 9, 2026. The company stated that his resignation was not due to any disagreement with the company on operations, policies, or practices. In response, the Board decided to reduce its size from eight to seven directors and will not fill the resulting vacancy at this time. The Board formally expressed its appreciation for Mr. Eldred’s service and contributions.
PetVivo Holdings, Inc. (PETV) furnished an investor presentation as Exhibit 99.1 via an 8‑K. The Company states representatives may use this presentation at investor conferences and other forums, and it may also appear on the corporate website.
The information is provided under Regulation FD, Item 7.01, is furnished and not deemed filed under Section 18 of the Exchange Act, and is not incorporated by reference into other filings except as specifically referenced. The exhibit is titled “PetVivo Holdings, Inc. Investor Presentation” and is dated November 2025.
PetVivo Holdings (PETV) expanded its Board to eight directors and appointed Josh Ruben, effective October 28, 2025. Ruben, age 39, was deemed “independent” under Exchange Act rules and will serve until the next annual meeting and until a successor is elected and qualified.
Ruben is Managing Director of Life Sciences at Trinity Capital and previously led Life Science Tools and Diagnostics coverage at RBC Capital Markets after nine years at Wells Fargo Securities. His compensation will align with the Company’s non-employee director program on a pro‑rated basis. He has no disclosed related-party transactions or family relationships with current directors or officers and has not yet been appointed to any committees.